C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics presented biomarker data from its Phase 1 trial of cemsidomide combined with dexamethasone in relapsed/refractory multiple myeloma patients, demonstrating robust T-cell activation and immune cell function. The company also shared preliminary data from a Phase 1b trial combining cemsidomide with elranatamab, showing enhanced CD8+ T-cell expansion and prevention of T-cell exhaustion. The 75 µg dose level was declared safe, allowing advancement to dose escalation and expansion cohorts with full data expected in mid-2027.